Laidlaw Wealth Management’s Gilead Sciences GILD Stock Holding History

Laidlaw Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$229K	Sell	1,645 -263	-14%	-$36.8K	0.8%	37
2025 Q4	$234K	Buy	+1,908	New	+$232K	0.72%	40
2024 Q1	–	Sell	-3,369	Closed	-$273K	–	198
2023 Q4	$273K	Buy	3,369 +95	+3%	+$7.39K	0.1%	193
2023 Q3	$245K	Buy	3,274 +115	+4%	+$8.85K	0.08%	226
2023 Q2	$243K	Sell	3,159 -788	-20%	-$62.8K	0.05%	297
2023 Q1	$328K	Sell	3,947 -176	-4%	-$14.6K	0.07%	247
2022 Q4	$354K	Sell	4,123 -334	-7%	-$26.4K	0.08%	241
2022 Q3	$275K	Sell	4,457 -456	-9%	-$28.8K	0.06%	253
2022 Q2	$304K	Buy	4,913 +43	+0.9%	+$2.66K	0.06%	263
2022 Q1	$290K	Buy	4,870 +131	+3%	+$8.37K	0.05%	306
2021 Q4	$344K	Buy	+4,739	New	+$326K	0.06%	280
2021 Q1	–	Sell	-3,693	Closed	-$215K	–	272
2020 Q4	$215K	Buy	+3,693	New	+$223K	0.05%	325
2020 Q2	–	Sell	-3,490	Closed	-$261K	–	186
2020 Q1	$261K	Buy	+3,490	New	+$241K	0.17%	121

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Laidlaw Wealth Management's GILD Position: Q1 2026 in Review

Laidlaw Wealth Management reduced its Gilead Sciences (GILD) stake by 14% in Q1 2026, selling an estimated $36.8K and leaving 1,645 shares worth $229K. The position accounts for 0.8% of the portfolio, ranked #37.

Laidlaw Wealth Management first reported a position in GILD in Q1 2020 and has held it in 13 quarters since. The position peaked at $354K in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Laidlaw Wealth Management held 1,645 shares of Gilead Sciences worth $229K as of Q1 2026.
Laidlaw Wealth Management sold 263 Gilead Sciences shares in Q1 2026, an estimated $36.8K.
Gilead Sciences made up 0.8% of Laidlaw Wealth Management's portfolio in Q1 2026, its #37 holding.
Laidlaw Wealth Management first reported a position in Gilead Sciences in Q1 2020 and has held it in 13 quarters since.
Laidlaw Wealth Management's Gilead Sciences position peaked at $354K in Q4 2022.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Laidlaw Wealth Management's 13F filing for Q1 2026, filed 6 May 2026.